Genetic Testing Giant 23andMe Going Bankrupt Sparking Data Concerns

The once-celebrated DNA testing company 23andMe, famous for promising Americans personal insight through their genetic code, has officially collapsed. On Sunday night, the company filed for Chapter 11 bankruptcy protection in Missouri federal court—marking a stunning downfall for a business once valued at $6 billion.

CEO Anne Wojcicki Resigns Amid Financial Chaos

Anne Wojcicki, the Silicon Valley elite who co-founded 23andMe in 2006, is out as CEO effective immediately. She’s staying on the board, but her days of steering the ship are over. Joseph Selsavage, the company’s chief financial officer, has been appointed interim CEO.

In a carefully worded statement on X (formerly Twitter), Wojcicki admitted, “We have had many successes but I equally take accountability for the challenges we have today.” Still, she made it clear she’s not walking away entirely, saying she remains committed to the company’s future.

From Billion-Dollar Darling to Wall Street Disaster

23andMe soared to fame thanks to its at-home DNA kits, offering a blend of ancestry reports and health risk predictions. It went public in 2021 through a SPAC deal that valued it at $3.5 billion. But since then, things have unraveled—fast.

As of Monday, the company’s market cap had plummeted to just $25 million. Stockholders have watched their investments disintegrate while executives searched for a working business model. Attempts to shift into drug development and research partnerships fell flat.

Special Committee Repeatedly Rejected Wojcicki’s Private Buyout Bids

In a last-ditch effort to regain control, Wojcicki made several offers to take the company private again. A special committee of independent board members rejected each one, including her latest proposal earlier this month, calling it inadequate.

Bankruptcy Filing Reveals Massive Debt and Asset Fire Sale Plan

According to the bankruptcy filing, 23andMe holds an estimated $100 million to $500 million in both assets and liabilities. The company plans to sell off its assets during the Chapter 11 process and is soliciting bids over a 45-day period. Wojcicki says she’ll attempt to buy back the company herself—as a private bidder.

Data Privacy Storm Hits Hard

For millions of Americans, 23andMe wasn’t just a novelty—it meant handing over the most personal information possible: their DNA. But the company’s lax security shattered public trust.

In October 2023, hackers breached the company’s systems and accessed the genetic information of nearly 7 million users. The fallout was swift. California Attorney General Rob Bonta issued a warning last week urging consumers to delete their genetic data from the platform altogether.

While 23andMe insists no changes will be made to how customer data is handled during bankruptcy, that may be cold comfort to users burned by the breach. Many privacy-minded Americans have long raised concerns about giving Big Tech access to their biological blueprint.

“I will continue to tirelessly advocate for customers to have choice and transparency with respect to their personal data,” Wojcicki wrote—but for many, that promise may be too little, too late.

The Fall of a Genomics Empire

23andMe was once hailed as a revolutionary biotech disruptor. But behind the marketing glitz, the company’s business model failed to deliver sustainable profits—and its handling of sensitive user data left a trail of controversy.

What began as a personal genomics movement has now ended in a courtroom, with creditors circling and leadership in disarray. For Americans skeptical of tech giants and protective of their privacy, 23andMe’s downfall is more than a business failure—it’s a cautionary tale.

Bottom Line

Another Silicon Valley dream just crashed—and this time, your DNA might’ve gone down with it.